| Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury T Li, Z Zhang, SC Kolwicz, L Abell, ND Roe, M Kim, B Zhou, Y Cao, ... Cell metabolism 25 (2), 374-385, 2017 | 369 | 2017 |
| Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells X Yang, ML Rodriguez, A Leonard, L Sun, KA Fischer, Y Wang, ... Stem Cell Reports 13 (4), 657-668, 2019 | 278 | 2019 |
| Metabolism in cardiomyopathy: every substrate matters J Ritterhoff, R Tian Cardiovascular research 113 (4), 411-421, 2017 | 278 | 2017 |
| Metabolic Remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis J Ritterhoff, S Young, O Villet, D Shao, FC Neto, LF Bettcher, YWA Hsu, ... Circulation Research 126 (2), 182-196, 2020 | 189 | 2020 |
| Glucose promotes cell growth by suppressing branched-chain amino acid degradation D Shao, O Villet, Z Zhang, SW Choi, J Yan, J Ritterhoff, H Gu, D Djukovic, ... Nature communications 9 (1), 2935, 2018 | 153 | 2018 |
| A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway LH Lehmann, ZH Jebessa, MM Kreusser, A Horsch, T He, M Kronlage, ... Nature medicine 24 (1), 62-72, 2018 | 121 | 2018 |
| S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll‐like receptor 4 D Rohde, C Schön, M Boerries, I Didrihsone, J Ritterhoff, KF Kubatzky, ... EMBO molecular medicine 6 (6), 778-794, 2014 | 99 | 2014 |
| Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges J Ritterhoff, R Tian Nature Reviews Cardiology 20 (12), 812-829, 2023 | 85 | 2023 |
| S100A1: a multifaceted therapeutic target in cardiovascular disease D Rohde, J Ritterhoff, M Voelkers, HA Katus, TG Parker, P Most Journal of cardiovascular translational research 3, 525-537, 2010 | 83 | 2010 |
| Heart failure gene therapy: the path to clinical practice ST Pleger, H Brinks, J Ritterhoff, P Raake, WJ Koch, HA Katus, P Most Circulation research 113 (6), 792-809, 2013 | 74 | 2013 |
| Targeting S100A1 in heart failure J Ritterhoff, P Most Gene therapy 19 (6), 613-621, 2012 | 60 | 2012 |
| Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model C Weber, I Neacsu, B Krautz, P Schlegel, S Sauer, P Raake, J Ritterhoff, ... Gene therapy 21 (2), 131-138, 2014 | 51 | 2014 |
| S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials D Rohde, H Brinks, J Ritterhoff, G Qui, S Ren, P Most Journal of molecular and cellular cardiology 50 (5), 777-784, 2011 | 46 | 2011 |
| Upregulation of mitochondrial ATPase inhibitory factor 1 (ATPIF1) mediates increased glycolysis in mouse hearts B Zhou, A Caudal, X Tang, JD Chavez, TS McMillen, A Keller, O Villet, ... Journal of Clinical Investigation 132 (10), e155333, 2022 | 41 | 2022 |
| S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation P Most, C Lerchenmüller, G Rengo, A Mahlmann, J Ritterhoff, D Rohde, ... Circulation research 112 (1), 66-78, 2013 | 38 | 2013 |
| Gene therapy targets in heart failure: the path to translation PWJ Raake, H Tscheschner, J Reinkober, J Ritterhoff, HA Katus, WJ Koch, ... Clinical Pharmacology & Therapeutics 90 (4), 542-553, 2011 | 35 | 2011 |
| Increasing fatty acid oxidation elicits a sex-dependent response in failing mouse hearts J Ritterhoff, TS McMillen, O Villet, S Young, SC Kolwicz Jr, T Senn, ... Journal of molecular and cellular cardiology 158, 1-10, 2021 | 29 | 2021 |
| Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology D Rohde, M Busch, A Volkert, J Ritterhoff, HA Katus, K Peppel, P Most Future cardiology 11 (3), 309-321, 2015 | 25 | 2015 |
| Branched-chain keto acids inhibit mitochondrial pyruvate carrier and suppress gluconeogenesis in hepatocytes K Nishi, A Yoshii, L Abell, B Zhou, R Frausto, J Ritterhoff, TS McMillen, ... Cell Reports 42 (6), 2023 | 23 | 2023 |
| S100A1 DNA-based inotropic therapy protects against proarrhythmogenic ryanodine receptor 2 dysfunction J Ritterhoff, M Völkers, A Seitz, K Spaich, E Gao, K Peppel, ST Pleger, ... Molecular Therapy 23 (8), 1320-1330, 2015 | 18 | 2015 |
